Cizzle Biotechnology Holdings plc (LON:CIZ), the UK-based developer of diagnostic tests for early-stage cancer, is pleased to announce that a patent application covering the Company’s core methods to measure the CIZ1B lung cancer biomarker has now been allowed by the U.S. Patent and Trademark Office. This additional patent further enhances the Company’s strong patent portfolio, especially in the key market of the USA and follows the grant of a patent in Canada, as announced on 4 February 2026.
As with the recent patent granted in Canada, the USPTO patent, ‘Use of a fibrinogen capture agent to detect a CIZ1B variant’, concerns a two-step test format developed by Cizzle at the University of York. This test format is licensed to Cizzle Bio Inc for use in North America and the Caribbean, and these new patents strengthen BIO’s position as they prepare to launch the test and establish a robust position for commercialising the Company’s innovative and proprietary technology.
Background
The CIZ1B biomarker test is the product of work by Professor Dawn Coverley, the Company’s founder and CSO, and her research team at the University of York, initially supported by both UK industry and charity sector research grants.
The Company’s commercial strategy is to licence globally its proprietary test for the CIZ1B biomarker for use in the early detection of lung cancer. As such, Cizzle Biotechnology’s patent portfolio and technology know-how is central to securing future licensing and royalty revenue. Developing a strong patent portfolio in North America is intended to enable BIO to establish a leading market position and supports its partnership programme with specialist clinical laboratories and hospitals, enabling market penetration to ensure the test is available to as many clinicians and patients as possible.
Cizzle Biotechnology also has been granted patent protection from the European Patent Office and intends to secure further licensing partnerships with accredited facilities in the UK and Europe, including the NHS. Bringing the CIZ1B biomarker test to market will provide valuable new solutions applicable to the current NHS cancer plan which aims to improve cancer survival by diagnosing 75% of cancers at stages 1 and 2 by 2028.
Commenting, Dawn Coverley, Chief Scientific Officer of Cizzle Biotechnology, said:
“Strengthening of the Company’s patent portfolio with this grant by the USPTO is timely and perfectly aligned with recent efforts to take the CIZ1B ELISA test format to market with our US partner Cizzle Bio Inc.”
